Publications

Publications

  • Nancarrow DJ*, Handoko HY, Smithers BM*, Gotley DC*, Drew PA, Watson DI, Clouston AD, Hayward NK & Whiteman DC. Genome-Wide Copy Number Analysis in Esophageal Adenocarcinoma Using High- Density Single-Nucleotide Polymorphism Arrays. Cancer Research (2008) 68;4163-4172.
  • Beck P, Mayne GC, Astill D*, Irvine T, Watson DI, Dijckmeester WA, Wijnhoven BPL, Hussey DJ*. Accuracy of identification of tissue types in endoscopic oesophageal mucosal biopsies used for molecular biology studies. Clinical and Experimental Gastroenterology (2009) 2;1-7.
  • Dijckmeester WA, Wijnhoven BPL, Watson DI, Leong MP, Michael MZ*, Mayne GC, Bright T, Astill D*, Hussey DJ*. MicroRNA-143 and -205 Expression in Neosquamous Esophageal Epithelium Following Argon Plasma Ablation of Barrett’s Esophagus. J Gastrointest Surg (2009) 13;846-853.
  • Smith CM, Watson DI, Michael MZ*, Hussey DJ*. MiRNAs, development of Barrett’s esophagus, and progression to esophageal adenocarcinoma. World J Gastroenterol (2010) 16:531-537.
  • Antonsson A, Nancarrow DJ*, Brown IS, Green AC, Drew PA, Watson DI, Hayward NK, Whiteman DC. High-risk human papillomavirus in oesophageal squamous cell carcinoma. International J Cancer (2010) – In Press.
  • Hummel R, Hussey DJ*, Michael MZ*, Bruwer M, Haier J, Watson DI. MiRNAs and their association with loco-regional staging and survival following surgery for esophageal cancer. Ann Surg Oncol (2010) DOI:10.1245/s10434-010-1213-y (published online)..
  • Wijnhoven BPL, Hussey DJ*, Watson DI, Tsykin A, Smith CM, Michael MZ* (& vanderHoek M, Astill D, Tilanus HW, Mayne GC). MicroRNA profiling of Barrett’s oesophagus and oesophageal adenocarcinoma. Br J Surg (2010) 97;853-861.
  • Botelho NK, Schneiders FI, Lord SJ, Freeman AK, Tyagi S, Nancarrow DJ*, Hayward NK, Whiteman DC, Lord RV. Gene expression alterations in formalin-fixed, paraffin-embedded Barrett's esophagus and esophageal adenocarcinoma tissues. Cancer Biol Ther. 2010 Jul 26;10(2).
  • Hirst NG, Gordon LG*, Whiteman DC, Watson DI, Barendregt JJ. Is endoscopic surveillance for non-dysplastic Barrett’s esophagus cost-effective? Review of economic evaluations. J Gastroenterol & Hepatol 2011; 26:247-254
  • Smithers BM*, Fahey P, Corish T, Gotley DC*, Falk G, Smith G*, Kiroff G, Clouston A, Watson DI, Whiteman DC. Symptoms, investigations and management of patients with cancer of the oesophagus and gastro-oesophageal junction in Australia. Med J Aust – In Press.
  • Phillips W, Lord RVL, Nancarrow D, Watson DI, Whiteman DC. Barrett’s oesophagus. J Gastroenterol Hepatol 2011;26:639-48
  • Tyagi S*, Stark M, Hayward N, Whiteman D, Nancarrow D*. webFOG: A web tool to Map Genomic Features on to Genes. Biochem Biophys Res Commun. 2010;401:447-50
  • Haiart S, Watson DI, Leong M, Astill D*, Bright T, Hussey DJ*. MiR-196a and miR-101 expression in Barrett’s oesophagus in patients with medically vs. surgically treated gastro-esophageal reflux. BMC Research Notes 2011, 4:41 doi:10.1186/1756-0500-4-41.
  • Smith CM, Watson DI, Leong MPL, Mayne GC, Michael MZ*, Wijnhoven BPL, Hussey DJ*. MiR-200 family expression in Barrett’s epithelium differs from gastric and duodenal epithelia and is downregulated upon progression to oesophageal adenocarcinoma. World J Gastroenterol 2010;16:531-7.
  • Hummel R, Hussey DJ, Michael MZ, Bruwer M, Haier J, Watson DI. MiRNAs and their association with loco-regional staging and survival following surgery for esophageal cancer. Ann Surg Oncol (2011) 18:253-260.
  • Smith CM, Watson DI, Leong MPL, Mayne GC, Michael MZ, Wijnhoven BPL, Hussey DJ. MiR-200 family expression in Barrett’s epithelium differs from gastric and duodenal epithelia and is downregulated upon progression to oesophageal adenocarcinoma. World J Gastroenterol (2011) 17:1036-1044.
  • Hummel R, Watson DI, Smith C, Kist J, Michael MZ, Bruewer M, Haier J, Hussey DJ. MiR-148a improves sensitivity to cisplatin and 5-FU in sensitive and resistant esophageal adeno- and squamous cell carcinoma cell lines. J Gastrointest Surg (2011) 15:429-438.
  • Nancarrow DJ, Clouston AD, Smithers BM, Gotley DC, Drew PA, Watson DI, Tyagi S, Hayward NK, Whiteman DC. Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett’s esophagus and esophageal adenocarcinoma. PLOS One (2011) 6;e22513.
  • Hummel R, Wang T, Watson DI, Michael MZ*, Van der Hoek M, Joerg Haier J, Hussey DJ*. Chemotherapy-induced modification of microRNA expression in esophageal cancer. Oncology Reports (2011) 26:1011-1017.
  • Gordon LG*, Eckermann S*, Hirst NG, Watson DI, Mayne GC, Fahey P, Whiteman DC. Health care use and medical costs for managing oesophageal cancers. Br J Surg (2011) 98:1589-1598.
  • Thrift AP, Nagle CM, Fahey P, Russell A, Smithers BM, Watson DI, Whiteman DC. The influence of demographic and lifestyle factors on oesophageal squamous cell carcinoma survival. Int J Cancer – In Press.
  • Gordon LG, Hirst NG, Mayne GC, Watson DI, Bright T, Cai W, Barbour AP, Smithers BM, Whiteman DC, Simon Eckermann. Modeling the cost-effectiveness of strategies for treating esophageal adenocarcinoma and high grade dysplasia. J Gastrointest Surg (2012) 16:1451-1461.
  • Watson DI. Oesophageal adenocarcinoma – the men’s health problem you don’t want to have! (Editorial) ANZ J Surg (2012) 82:571-572.
  • Chisholm JA, Mayne GC, Hussey DJ, Watson DI. Molecular biomarkers and ablative therapies for Barrett's esophagus. Expert Review of Gastroenterology & Hepatology (2012) 6:567-581.
  • Mayne GC, Watson DI, Hussey DJ. COX-2 mRNA expression is increased in esophageal mucosal cells following exposure to a proton pump inhibitor. ANZ J Surg (2012) 82:592-8.
  • Mayne GC, Hussey DJ, Watson DI. MicroRNAs and esophageal cancer - implications for pathogenesis and therapy. Current Pharmaceutical Design (2013) 19:1211-1226.
  • Sukocheva OA, Wee C, Ansar A, Hussey DJ, Watson DI. Effect of estrogen on growth and apoptosis in esophageal adenocarcinoma cells. Dis Esoph (2012) DOI: 10.1111/dote.12000 (published online).
  • Smith CM, Michael MZ, Watson DI, Tan G, Astill D, Hummel R, Hussey DJ. Impact of gastroesophageal reflux on microRNA expression, location and function. BMC Gastroenterol (2013) 13:4.
  • Mayne GC, Hussey DJ, Watson DI. Can microRNA profiling allow us to determine which patients with esophageal cancer will respond to chemoradiotherapy? (Key paper evaluation). Expert Review of Anticancer Therapy (2013) – In Press.
  • Clemons, N.J., D.H. Wang, D. Croagh, A. Tikoo, C.M. Fennell, C. Murone, A.M. Scott, D. N. Watkins, W.A. Phillips. Sox9 drives columnar differentiation of esophageal squamous epithelium: a possible role in the pathogenesis of Barrett’s esophagus. Am J Physiol Gastrointest Liver Physiol. 303(12):G1335-1346, 2012.